No abstract

61.7%, LP 25.0% and LN 55.5% ( Figure 1B). The median LRS was 4 (range: 1-12). Low LRS (<¼ 4) was significantly correlated with longer survival after LR (low score 16.4 vs high score 9.8 months, p¼0.03). Of 6 locations, first recurrence at CW (negative 16 vs positive 9.8 months, p¼0.044) and LN (negative 17.2 vs positive 9.2 months, p¼0.015) had significant negative prognostic impact on OS. In subgroup analysis, LRS was significantly higher after eP/D compared to EPP (median LRS: 6 vs 4, p<0.001), but survival after LR was significantly longer after eP/D compared to EPP (14.6 vs 9.6 months, p¼0.004). Conclusion: LRS might be a useful prognosticator in MPM patients with LR after MMT and might be helpful for further use as second line treatment allocation tool.